The EU AI Act Explained: What Every Pharma Leader Needs to Know

The EU AI Act is not just a compliance issue — it’s a strategic point for every pharma and healthcare leader using AI.

With enforcement beginning in 2026, the Act classifies most healthcare AI systems — from clinical decision support tools to AI-powered medical devices — as “high-risk”, triggering new and intensive requirements: transparency, data integrity, human oversight, and continuous monitoring.

Download this deep-dive analysis to understand:

  • What the EU AI Act really means for clinical trials, R&D, diagnostics, and digital health tools
  • How high-risk AI will be regulated and why most pharma use cases fall into this category
  • Why acting now creates a strategic edge, not just legal compliance